These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vaccination as a therapeutic approach to Alzheimer's disease. Wisniewski T; Boutajangout A Mt Sinai J Med; 2010; 77(1):17-31. PubMed ID: 20101719 [TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Wisniewski T; Boutajangout A Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091 [TBL] [Abstract][Full Text] [Related]
4. Novel immunological approaches for the treatment of Alzheimer's disease. Sabharwal P; Wisniewski T Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi; 2014; 14(3):139-151. PubMed ID: 25429302 [TBL] [Abstract][Full Text] [Related]
5. Murine models of Alzheimer's disease and their use in developing immunotherapies. Wisniewski T; Sigurdsson EM Biochim Biophys Acta; 2010 Oct; 1802(10):847-59. PubMed ID: 20471477 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. Goñi F; Prelli F; Ji Y; Scholtzova H; Yang J; Sun Y; Liang FX; Kascsak R; Kascsak R; Mehta P; Wisniewski T PLoS One; 2010 Oct; 5(10):e13391. PubMed ID: 20967130 [TBL] [Abstract][Full Text] [Related]
7. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Boutajangout A; Wisniewski T Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638 [TBL] [Abstract][Full Text] [Related]
8. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551 [TBL] [Abstract][Full Text] [Related]
11. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. Goñi F; Herline K; Peyser D; Wong K; Ji Y; Sun Y; Mehta P; Wisniewski T J Neuroinflammation; 2013 Dec; 10():150. PubMed ID: 24330773 [TBL] [Abstract][Full Text] [Related]
13. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. Tarawneh R; Holtzman DM CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934 [TBL] [Abstract][Full Text] [Related]
18. Active full-length DNA Aβ Rosenberg RN; Fu M; Lambracht-Washington D Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039 [TBL] [Abstract][Full Text] [Related]
19. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Nitsch RM; Hock C Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453 [TBL] [Abstract][Full Text] [Related]